Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains

References

• Achim CL, Heyes MP, Wiley C. Quantitation of human immunodeficiency virus immune activation factors, and quinolininc acid in AIDS brains. J Clin Invest 1993; 91: 2769–2775
   PubMed Web of Science ®Google Scholar
• Adolfsson R, Gottfries CG, Roos BE, Winblad B. Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related with age, and a review of literature. J Neurol Transm 1979; 45: 81–105
   PubMed Web of Science ®Google Scholar
• Ances BM, Roc AC, Wang J, Korczkowski M, Okawa J, Stern J, Kim J, Wolf R, Lawler K, Kolson DL, Detre JA. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 2006; 66: 862–866
   Web of Science ®Google Scholar
• Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86–92
   PubMed Web of Science ®Google Scholar
• Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64: 529–536
   PubMed Web of Science ®Google Scholar
• Arai H, Kosaka K, Lizuka R. Changes in biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 1984; 43: 388–393
   PubMed Web of Science ®Google Scholar
• Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993; 43: 2099–2104
   PubMed Web of Science ®Google Scholar
• Bagasra O, Levi E, Bobroski L. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996; 10: 573–585
   PubMed Web of Science ®Google Scholar
• Banks WA, Robinson SM, Wolf KM, Bess JW, Jr, Arthur LO. Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated. Neuroscience 2004; 128: 143–153
   PubMedGoogle Scholar
• Bennet BA, Rusyniak DE, Hollingsworth CK. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 1995; 705: 168–176
   Google Scholar
• Berger JR, Kumar M, Kumar A, Fernandez JB, Levine B. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS. 1994; 8: 67–71
   PubMed Web of Science ®Google Scholar
• Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirology 1997; 40: 122–131
   PubMedGoogle Scholar
• Berger JR, Arendt G. HIV-dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000; 14: 214–221
   PubMed Web of Science ®Google Scholar
• Bobardt MD, Salmon P, Wang L, Esko JD, Gabzuda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 2004; 78: 6567–6584
   PubMed Web of Science ®Google Scholar
• Brew BJ. HIV-1 related neurological disease. J Acquired Immune Defic Syndr 1993; 6(Suppl 1)S10–S15
   PubMedGoogle Scholar
• Broder CC, Dimitrov DS. HIV and the 7-transmembrane domain receptors. Pathobiology 1996; 64: 171–179
   PubMed Web of Science ®Google Scholar
• Castello JMB, Courtney MG, Melrose RJ, Stern CE. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise. Arch Neurol 2007; 64: 1275–1280
   Google Scholar
• Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3methoxytyramine levels in human basal ganglia. J Neural Transm 1976; 38: 271–276
   PubMed Web of Science ®Google Scholar
• Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller EN. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999; 53: 782–789
   PubMed Web of Science ®Google Scholar
• Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitti G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Navia BA. A multicenter in vivo protons-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004; 23: 1336–1347
   PubMed Web of Science ®Google Scholar
• Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135–1148
   PubMed Web of Science ®Google Scholar
• Danna Consortium. 1998. A randomized double blind placebo controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Danna Consortium on the therapy of HIV-dementia and related cognitive disorders. Neurology, 50:645–651
   Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539–1545
   PubMed Web of Science ®Google Scholar
• Eden A, Price RW, Spudich S, Fuchs L, Hargberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196: 1779–1783
   PubMed Web of Science ®Google Scholar
• Ellis, R, Childers, ME, Kumar, AM, Kumar, M, Goetz, T, Caligiuri, M. 2004. Decreased cerebrospinal fluid dopamine correlates with impaired motor skills in HIV-1 infection and methamphetamine dependence. Presented at the Society for Neuroscience, 34th Annual Meeting, San Diego, Oct 23–27.
   Google Scholar
• Fillipi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA. Regression of HIV encelopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998; 206: 491–498
   Google Scholar
• Ensoli F, Wang H, Fiorelli V, Zeichner S L, Cristofero De M R, Luzi G, Thiele CJ. HIV-1 infection and the developing nervous system: lineage-specific regulation of viral gene expression and replication in distinct neuronal precursors. J NeuroVirol 1997; 3: 290–298
   Web of Science ®Google Scholar
• Garris PA, Ciolkowski EL, Pastore P, Weightman RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbence of the rat brain. J Neurosci 1994; 14: 6084–6093
   PubMed Web of Science ®Google Scholar
• Georgiou FM, Gonenc A, Waldrop-Valverde D, Kuker RA, Ezzuddin SH, Sfakianakis GN, Kumar M. Analysis of the effect of injecting drug use and HIV-1 infection on 18F-FDG PET brain metabolism. J Nucl Med 2008; 49: 1999–2005
   PubMed Web of Science ®Google Scholar
• Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidvudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses 1994; 10: 947–51
   PubMedGoogle Scholar
• Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantification of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38: 755–762
   PubMed Web of Science ®Google Scholar
• Gottfries CG. Neurochemical aspects on aging and disease with cognitive impairment. J Neurosci Res 1990; 27: 541–547
   PubMed Web of Science ®Google Scholar
• Gray F, Adle-Biassette H, Chreien F, Lorin de la Grandmaison G, Force G, Keohane C. Neuropatholoy and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesion of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol 2001; 20: 146–155
   PubMed Web of Science ®Google Scholar
• Harrison MIJ, Newman SP, Hall-Craggs MA, et al. Evidence of CNS impairment in HIV-1 infection: clinical, neuropsychological, EEG, and MRI/MNRS study. J Neurosurg Psychiatr 1998; 5: 301–307
   Google Scholar
• Herregodts P, Ebinger G, Michotte Y. Distribution of monoamines in human brain: evidence for neurochemical heterogeneity in subcortical as well as cortical areas. Brain Res 1991; 542: 300–306
   Google Scholar
• Heyes M.P, Saito K, Markey S P. Human macrophages convert l-tryptophan in to the neurotoxin quinolininc acid. Biochem J 1992; 283: 633–635
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Castellon SA, Hardy DJ, Farinpour R, Newton J, Singer E. Methylphenidate improves HIV-associated cognitive slowing. J Neuropsychiatry Clin Neurosci 2001; 13: 248–254
   PubMed Web of Science ®Google Scholar
• Ho D, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Eng J Med 1985; 313: 1493–1497
   PubMed Web of Science ®Google Scholar
• Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 11: 1558–156
   Google Scholar
• Itoh K, Mehraein P, Weis S. Neuronal damage of the substantia nigra in HIV-infected brains. Acta Neuropathol 2000; 99: 376–384
   PubMed Web of Science ®Google Scholar
• Jernigan TL, Archibald S, Hesselink JR. Magnetic resonance imaging morphometric analysis of cerebral volume loss in human deficiency virus infection. Arch Neurol 1993; 50: 250–255
   PubMed Web of Science ®Google Scholar
• Johnson RT, Glass JD, McArthur JC, Chesebro BW. Quantitation of human deficiency virus in brains of demented and non-demented patients with acquired immunodeficiency syndrome. Ann Neurol 1996; 39: 392–395
   PubMed Web of Science ®Google Scholar
• Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ 2007; 14: 296–305
   PubMed Web of Science ®Google Scholar
• Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol 1991; 48: 1281–1284
   PubMedGoogle Scholar
• Kieburtz KD, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine D. Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection. Arch Neurol 1996; 53: 155–158
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289–294
   PubMed Web of Science ®Google Scholar
• Koutsillieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. Parkinson in HIV dementia. J Neural Transm 2002; 109: 767–775
   Google Scholar
• Kumar AM, Berger JR, Eisdorfer C, Fernandez JB, Goodkin K, Kumar M. Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology 2001; 44: 13–18
   Google Scholar
• Kumar AM, Borodowsky I, Fernandez JB, Gonzalez L, Kumar M. Human immunodeficiency virus type 1 RNA levels in different brain regions of human brain: quanyification using real-time reverse transcriptase-polymerase chain reaction. J NeuroVirol 2007; 13: 210–224
   PubMed Web of Science ®Google Scholar
• Kumar AM, Fernandez JB, Antoni MH, Eisdorfer S, Kumar M. Catecholamines quantification in body fluids using isocratic, reverse phase HPLC-CoulArray multi-electrode chemical detector system: Investigation of sensitivity, stability, and reproducibility. J Liquid Chromatogr Relat Technol 2003; 26: 3433–3451
   Web of Science ®Google Scholar
• Kumar AM, Fernandez JB, Gonzalez L, Kumar M. Ultramicro quantification of dopamine and homovanillic acid in human brain tissue: quest for higher recovery and sensitivity with CoulArray HPLC-ECD system. J Liquid Chromatogr Relat Technol 2006; 29: 777–799
   Web of Science ®Google Scholar
• Kure K, Weidenheim KM, Lyman WD, Dickson DW. Morphology and distribution of HIV-1 gp41-positive microgila in subacute AIDS encephalitis: pattern of involvement resembling a multisystem degeneration. Acta Neuropahol (Berl) 1990; 80: 393–400
   PubMed Web of Science ®Google Scholar
• Larsson M, Hagberg L, Forsman A, Norkrans G. Cerebrospinal fluid catecholamine metabolites in HIV-1 infected patients. J Neurosci Res 1991; 28: 406–409
   PubMed Web of Science ®Google Scholar
• Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia [review]. Neuropsychiatry Neuropsychol Behav Neurol 1999; 12: 184–192
   PubMedGoogle Scholar
• Mackay AVP, Yates CM, Wright A, Hamilton P, Davies P. Regional distribution of monoamines and their metabolites in the human brain. J Neurochem 1986; 65: 135–153
   Google Scholar
• Magyar, R. 1993.Pharmacology of monoamine oxidase type B inhibitors. In: Inhibitors of monoamine oxidase B, pharmacology and clinical use in neurodegenerative disorders. Szelenyi I. BaselSwitzerland: Birkhauser. 125–143.
   Google Scholar
• Masliah E, Achim CL, Ge N, DeTeresa R, Terry D, Wiley CA. Spectrum of HIV associated neocortical damage. Ann Neurol 1992; 32: 85–93
   Google Scholar
• Maslin CLV, Kedzierska K, Webseter N, Muller W, Crowe S. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res 2005; 3: 303–317
   PubMedGoogle Scholar
• Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia [review]. Cell Death Differ 2005; 12(Suppl 1)893–904
   PubMedGoogle Scholar
• Merril JE, Chen ISV. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J 1991; 5: 2391–2397
   Google Scholar
• Mirsattari SM, Power C, Nath A. Parkinsonism with HIV infection. Movement Disord 1998; 13: 684–689
   Google Scholar
• Morgello S, Gelman BB, Kozlowski PB, Vinters HV, Masliah E, Cornford M, Cavert W, Marra C, Grant I, Singer EJ. The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious diseases. Neuropathol Appl Neurobiol 2001; 27: 326–335
   PubMed Web of Science ®Google Scholar
• Morgenson GJ, Yang CR. The contribution of basal forebrain to limbic-motor integration and the mediation of motivation to action. Adv Exp Med Biol 1991; 295: 267–273
   Google Scholar
• Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186(Suppl 2)S193–S198
   PubMed Web of Science ®Google Scholar
• Nath A, Anderson C, Jones M, Maragose W, Booz R, Mactutus C, Bell J, Hauser K, Mattson M. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000; 14: 222–227
   PubMed Web of Science ®Google Scholar
• Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 2006; 19: 358–361
   PubMed Web of Science ®Google Scholar
• Navia BA, Price RW. The acquired immune deficiency syndrome dementia complex as the presenting or sole manifestation of human immune deficiency virus infection. Arch Neurol 1987; 44: 65–69
   PubMedGoogle Scholar
• Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, Sharer LR, McComb RD, Swindells S, Soderland C, Gendelman HE. Mechanisms for the transendothelial migration of HIV-1 infected monocytes in to the brain. J Immunol 1996; 156: 1284–1295
   PubMed Web of Science ®Google Scholar
• Parra A, Ramirez-Peredo J, Larrea F, Cabrera V, Coutino B, Torres I, Angeles A, Perez-Romano B, Ruiz-Arguelles G, Ruiz-Arguelles A. Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin Endocrinol 2001; 54: 731–738
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leuk Biol 2003; 74: 691–701
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M. A model for monocyte migration through the blood brain barrier during HIV-1 encephalitis. J Immunol 1997; 158: 3499–3510
   PubMed Web of Science ®Google Scholar
• Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158: 1079–1083
   PubMed Web of Science ®Google Scholar
• Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, Haapasalo H, Krohn K. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 1995; 9: 1001–1008
   PubMed Web of Science ®Google Scholar
• Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood brain barrier by HIV. Neurology 1988; 38: 9–14
   PubMed Web of Science ®Google Scholar
• Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R. Nigral degeneration in acquired immunodeficiency syndrome (AIDS). Acta Neuropathol 1991; 82: 39–44
   PubMed Web of Science ®Google Scholar
• Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence of incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915–1921
   PubMed Web of Science ®Google Scholar
• Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996; 37: 1133–1141
   PubMed Web of Science ®Google Scholar
• Sacktor N, McDermott MP, Marder K, Schiffito G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol 2002; 8: 136–142
   PubMed Web of Science ®Google Scholar
• Sacktor N, Schiffito G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegeline in HIV-associated cognitive impairment. Pilot, placebo controlled study. Neurology 2000; 54: 233–235
   PubMed Web of Science ®Google Scholar
• Sardar AM, Czudek C, Reynolds GP. Dopamine deficits in the brain: The neurochemical basis of Parkinsonian symptoms in AIDS. Neuroreport 1996; 7: 910–912
   Google Scholar
• Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grunblatt E, ter Meulen V, Riederer P, Koutsilieri E. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkey due to microglia activation. J Neurochem 2005; 95: 377–387
   Google Scholar
• Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280: 67–71
   PubMed Web of Science ®Google Scholar
• Spokes EGS. An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and cholineacetylase in human post-mortem brain tissue. Brain 1979; 102: 333–346
   Google Scholar
• Stout JC, Ellis RJ, Jernigan TL, et al. HIV Neurobehavioral Research Center Group. Progressive cerebral volume loss in human deficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Arch Neurol 1998; 55: 161–168
   PubMedGoogle Scholar
• Taylor, M, Schweinsberg, BC, Alhassoon, OM, Gangavatana, A, Brown, GG, Young-Casey, C,Letendre, SL, Grant, I, the HNRC group. 2007. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. J NeuroVirol, 13:150–159.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, Antonori A, Giulianelli M, Tosi G, Fantoni M, Sampaolesi A, Noto P, Ippolito G, Wu AW. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 2004; 15: 254–259
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinore A, Narciso P. Persistence of neuropsychological deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45: 174–182
   PubMed Web of Science ®Google Scholar
• Volkow N, Fowler J, Gately S, Logan J, Wang G, Ding Y, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37: 1242–1256
   PubMed Web of Science ®Google Scholar
• Von Giesen HJ, ittsack HJ, Wenserski F, Koller H, Hefter H, Arendt G. Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. Arch Neurol 2001; 58: 1281–1286
   Google Scholar
• Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS. Decreased brain dopaminergic transporters in HIV-1 associated dementia patients. Brain 2004; 127: 2452–2458
   PubMed Web of Science ®Google Scholar
• Wester P, Bergstrom U, Erikson A, Gezelius C, Hardy J, Winblad B. Ventricular cerebrospinal fluid monoamine transmitters and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem 1990; 54: 1148–1156
   PubMedGoogle Scholar
• WHO/UNAIDS Agency. 2007. AIDS Epidemic Update, November, 2007
   Google Scholar
• Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Herman SA, Dalley P, Achim CL. Distribution of brain HIV load in AIDS. Brain Pathol 1998; 8: 277–284
   PubMed Web of Science ®Google Scholar
• Wiley CA, Shrie RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83: 7089–7093
   PubMed Web of Science ®Google Scholar
• Zauli G, Secchiero P, Luigi R, Gibellini D, Mirandola P, Mazzoni M, Milani MD, Dowd DR, Capitani S, Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 2000; 275: 4159–416
   Google Scholar